TY - JOUR
T1 - General scientific guidance for stakeholders on health claim applications
AU - Bresson, Jean Louis
AU - Burlingame, Barbara
AU - Dean, Tara
AU - Fairweather-Tait, Susan
AU - Heinonen, Marina
AU - Hirsch-Ernst, Karen Ildico
AU - Mangelsdorf, Inge
AU - McArdle, Harry
AU - Naska, Androniki
AU - Neuhäuser-Berthold, Monika
AU - Nowicka, Grazyna
AU - Pentieva, Kristina
AU - Sanz, Yolanda
AU - Siani, Alfonso
AU - Sjödin, Anders
AU - Stern, Martin
AU - Tomé, Daniel
AU - Turck, Dominique
AU - Van Loveren, Hendrik
AU - Vinceti, Marco
AU - Willatts, Peter
N1 - Publisher Copyright:
© 2016 European Food Safety Authority
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2016/1/18
Y1 - 2016/1/18
N2 - The European Food Safety Authority (EFSA) asked the Panel on Dietetic Products Nutrition and Allergies (NDA) to update the General guidance for stakeholders on the evaluation of Article 13.1, 13.5 and 14 health claims published in March 2011. Since then, the NDA Panel has completed the evaluation of Article 13.1 claims except for claims put on hold by the European Commission, and has evaluated additional health claim applications submitted pursuant to Articles 13.5, 14 and also 19. In addition, comments received from stakeholders indicate that general issues that are common to all health claims need to be further clarified and addressed. This guidance document aims to explain the general scientific principles applied by the NDA Panel for the evaluation of all health claims and outlines a series of steps for the compilation of applications. The general guidance document represents the views of the NDA Panel based on the experience gained to date with the evaluation of health claims, and it may be further updated, as appropriate, when additional issues are addressed.
AB - The European Food Safety Authority (EFSA) asked the Panel on Dietetic Products Nutrition and Allergies (NDA) to update the General guidance for stakeholders on the evaluation of Article 13.1, 13.5 and 14 health claims published in March 2011. Since then, the NDA Panel has completed the evaluation of Article 13.1 claims except for claims put on hold by the European Commission, and has evaluated additional health claim applications submitted pursuant to Articles 13.5, 14 and also 19. In addition, comments received from stakeholders indicate that general issues that are common to all health claims need to be further clarified and addressed. This guidance document aims to explain the general scientific principles applied by the NDA Panel for the evaluation of all health claims and outlines a series of steps for the compilation of applications. The general guidance document represents the views of the NDA Panel based on the experience gained to date with the evaluation of health claims, and it may be further updated, as appropriate, when additional issues are addressed.
KW - applications
KW - general principles
KW - guidance
KW - health claims
KW - scientific aspects
UR - http://www.scopus.com/inward/record.url?scp=85092678271&partnerID=8YFLogxK
U2 - 10.2903/j.efsa.2016.4367
DO - 10.2903/j.efsa.2016.4367
M3 - Article
AN - SCOPUS:85092678271
SN - 1831-4732
VL - 14
JO - EFSA Journal
JF - EFSA Journal
IS - 1
M1 - 4367
ER -